ALBERTDAVDBSEAlbert David Ltd-$MediumNeutral
Announced Tue, 12 May · 20:12 IST

Record date fixed on 30th July 2026 for the purpose of final dividend and determining members eligible to vote for 87th AGM.

Ceo Appointed ExternalManagement Changes View source PDF

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-10.5%1-day move
₹790.00
prior close
₹730.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.9-1.9-2.3-2.1-10.5-8.6-10.1-9.2-10.4-10.6-8.8-8.3-11.2
Up moveDown movePending
AI summary

Albert David Limited's Board meeting on May 12, 2026 approved several key items. The board appointed Mr. Amit Mahla as CEO, effective immediately, following the resignation of Mr. Umesh Manohar Kunte (Managing Director & CEO) who left on December 18, 2025. Financial results showed a significant decline - the company reported a full-year loss of Rs. 149.47 Lacs for FY26 compared to a profit of Rs. 1,720.08 Lacs in FY25. Quarterly Q4 revenue was Rs. 8,586.34 Lacs. The board recommended a final dividend of Rs. 5 per share (50% on Rs. 10 face value) for shareholder approval at the 87th AGM on August 6, 2026, with record date July 30, 2026. PwC was reappointed as internal auditors and S. Gupta & Co. as cost auditors for FY27. Statutory auditors L.B. Jha & Co. issued an unmodified opinion on the financial statements.

Likely market impact

The appointment of an experienced pharma executive like Amit Mahla (from JB Pharma, Cipla, Sun Pharma) may be seen as a positive step to reverse the company's declining profitability. However, the substantial drop in FY26 earnings will concern shareholders - the company swung from a profit of Rs. 17.2 crore to a loss. The dividend offer provides some cushion for investors.